ascent dt tab - Lomus Pharmaceuticals Pvt. Ltd.

ASCENT DT
Dosage Forms/Composition
Each tablet contains Aceclofenac 100mg
Pharmacological Index
Nonsteroidal Anti-Inflammatory Agent (NSAID)
INDICATION
For the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing
spondylitis
Contraindications
Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment;
pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with
infections.
Warnings/Precautions
Elderly, GI disease, ulcerative colitis, Crohn’s disease, haematological abnormalities,
hepatic porphyria, history of bronchial asthma, history of heart failure or hypertension,
mild renal, hepatic or cardiac impairment. May impair the ability to drive or operate
machinery.
Adverse Reactions
Diarrhoea, nausea, dyspepsia, abdominal pain, dizziness, rashes; increased LFTs.
Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.
Overdosage/Toxicology
Mangagement: Gastric lavage and treatment with activated characoal. Treatment is
supportive and symptomatic. Dialysis, haemoperfusion unlikely to be useful.
Drug Interactions
May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity
when used with diuretics or ciclosporin. Monitor serum potassium when used with
potassium-sparing diuretics and ACE inhibitors. May enhance activity of
anticoagulants. May increase risk of methotrexate toxicity when administered within
24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased
risk of convulsion with quinolones.
Mechanism of Action
Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic
properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the
production of prostaglandins.
Pharmacodynamics/Kinetics
Absorption: Well absorbed from the GI tract (oral); peak plasma concentrations after

1-3 hr.
Distribution: Protein-binding: 99%.
Excretion: Urine (as hydroxymetabolites); 4 hr (elimination half-life).
Usual Dosage
Adult: 100 mg bid.
Hepatic impairment: Reduce initial dose to 100 mg daily .
LOMUS Drug Information Center
Lomus Pharmaceuticals Pvt. Ltd.
P.O. Box No 4506, Lomus House (Corporate office),
Kailash Chour, Lazimpat, Kathmandu, Nepal
Ph: 4436396 (Hunting Line). Fx: 977-1-4436395
E-mail: druginfo@lomus.com.np